Novavax (NVAX) Interest Expenses (2010 - 2026)
Novavax (NVAX) posted quarterly Interest Expenses of $6.3 million for Q1 2026, up 9.98% year-over-year from $5.7 million in Q1 2025, and up 114.52% quarter-over-quarter from $2.9 million in Q4 2025.
Novavax (NVAX) Interest Expenses (2010 - 2026) Analysis & Trends
Novavax's Interest Expenses history runs 17 years deep, the most recent figure standing at $6.3 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 9.98% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $20.5 million (down 71.25% YoY), while the FY2025 annual figure was $1.0 billion, down 9.67% from the prior year.
- Interest Expenses for Q1 2026 stood at $6.3 million, up from $2.9 million in the prior quarter.
- The five-year high for Interest Expenses was $89.5 million in Q4 2023, with the low at $2.9 million in Q3 2023.
- The 5-year median for Interest Expenses is $5.5 million (2025), against an average of $13.0 million.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses soared 1846.23% in 2023, then plunged 94.86% in 2025.
- Novavax's Interest Expenses stood at $4.6 million in 2022, then jumped by 1846.23% to $89.5 million in 2023, then tumbled by 36.24% to $57.1 million in 2024, then slumped by 94.86% to $2.9 million in 2025, then jumped by 114.52% to $6.3 million in 2026.
- Business Quant data shows NVAX's Interest Expenses at $6.3 million in Q1 2026, $2.9 million in Q4 2025, and $7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 8.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.20 Mn |
| Jun 30, 2026 | 8.20 Mn |
| Mar 31, 2026 | 6.29 Mn |
| Mar 31, 2026 | 6.29 Mn |
| Dec 31, 2025 | 2.93 Mn |
| Dec 31, 2025 | 2.93 Mn |
| Sep 30, 2025 | 7.65 Mn |
| Sep 30, 2025 | 7.65 Mn |
| Jun 30, 2025 | 5.52 Mn |
| Jun 30, 2025 | 5.52 Mn |
| Mar 31, 2025 | 5.72 Mn |
| Mar 31, 2025 | 5.72 Mn |
| Dec 31, 2024 | 57.10 Mn |
| Dec 31, 2024 | 57.10 Mn |
| Sep 30, 2024 | 4.24 Mn |
| Sep 30, 2024 | 4.24 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Mar 31, 2024 | 4.11 Mn |
| Mar 31, 2024 | 4.11 Mn |